ReviewDiscover oncology2025
Emerging photothermal agents combined with immunotherapy for cancer treatment.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmunophotothermal therapy (IPTT), combining immune checkpoint inhibitors and photothermal therapy, represents a promising synergistic anticancer strategy that enhances tumour-specific immunity alongside localised thermal ablation.
aimThis review aims to summarise and critically analyse recent advancements in the development of photothermal agents for IPTT and their synergistic applications with immune checkpoint inhibitors.
methodsWe focus specifically on the progress in innovative photothermal agent materials, the underlying mechanisms of immunophotothermal synergy, and the resulting antitumor efficacy evidenced by preclinical and clinical findings.
conclusionsFurthermore, the key challenges hindering clinical translation and potential future directions are discussed. This comprehensive analysis highlights the current state and prospects of IPTT as an effective multimodal cancer treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.